The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.
S. Leijen
No relevant relationships to disclose
M. R. Middleton
No relevant relationships to disclose
P. Tresca
No relevant relationships to disclose
F. Kraeber-Bodere
Consultant or Advisory Role - Roche
Honoraria - PET reader
V. Dieras
Consultant or Advisory Role - Roche
Other Remuneration - Amgen; Pfizer; Roche
M. E. Scheulen
No relevant relationships to disclose
J. Tessier
Employment or Leadership Position - Roche
Z. X. Xu
Employment or Leadership Position - Roche
Stock Ownership - Roche
E. Shochat
Employment or Leadership Position - Roche
A. Walz
Employment or Leadership Position - Roche
J. Deutsch
Employment or Leadership Position - Roche
Stock Ownership - Roche
S. Blotner
Employment or Leadership Position - Roche
V. Lopez Valverde
Employment or Leadership Position - Roche
V. M. Naegelen
Employment or Leadership Position - Roche
J. H. M. Schellens
Consultant or Advisory Role - Roche
Research Funding - Roche
W. E. Eberhardt
Consultant or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Merck Sharp & Dohme; Novartis; OSI Pharmaceuticals; Pfizer; Roche; Sanofi ; Schering-Plough
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; OSI Pharmaceuticals; Pfizer; Roche; Sanofi ; Schering-Plough